Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut and focused on targeted protein degradation. Its news flow centers on progress across a pipeline of investigational PROTAC (PROteolysis TArgeting Chimera) protein degraders for oncology and neurodegenerative disorders.
On this ARVN news page, readers can follow company-issued updates on key programs such as vepdegestrant, an investigational PROTAC estrogen receptor degrader for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations; ARV-393, a BCL6 degrader in Phase 1 trials for relapsed/refractory non-Hodgkin lymphoma; ARV-806, a KRAS G12D degrader for solid tumors including pancreatic, colorectal and lung cancer; and ARV-102, a LRRK2 degrader being studied in Parkinson’s disease and other neurodegenerative conditions.
Typical ARVN news items include clinical data presentations at major scientific meetings, regulatory milestones such as acceptance of the New Drug Application for vepdegestrant by the U.S. Food and Drug Administration, and preclinical results that characterize the activity of new PROTAC candidates. Arvinas also uses press releases to describe collaboration developments with Pfizer, organizational changes, financial updates and other corporate actions disclosed in its SEC filings.
Investors, clinicians and researchers can use this news feed to track how Arvinas’ PROTAC platform is being applied to targets like estrogen receptor, BCL6, KRAS G12D and LRRK2, and to monitor the timing and content of data readouts, regulatory events and partnership announcements related to ARVN.
Arvinas (Nasdaq: ARVN) reported Phase 1 results for ARV-102 showing approximately ≥50% LRRK2 degradation in CSF by day 14, maintained through day 28, across 20–80 mg daily doses. ARV-102 showed dose-dependent CSF exposure, reduced endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB), and was generally well tolerated with no SAEs, supporting further development including a planned Phase 1b in PSP in Q2 2026.
Arvinas (Nasdaq: ARVN) will present Phase 1 human data for ARV-102, an oral PROTAC degrader targeting LRRK2, at AD/PD 2026 in Copenhagen. The presentation on March 18, 2026 at 3:30 PM CET covers safety, pharmacokinetics, and pharmacodynamics in participants with Parkinson’s disease.
Arvinas (Nasdaq: ARVN) reported 4Q and full‑year 2025 results and a corporate update on Feb 24, 2026. Key items: cash, cash equivalents and marketable securities of $685.4M at year‑end; cash runway into the second half of 2028; multiple clinical readouts and program milestones planned in 2026; Randy Teel named President and CEO.
Pipeline progress includes ARV‑102 AD/PD data in March 2026, ARV‑806 and ARV‑393 clinical updates in 2026, initiation of ARV‑027 healthy‑volunteer trial, and ARV‑6723 Phase 1 planned mid‑2026.
Arvinas (Nasdaq: ARVN) said management will participate in four investor conferences in early March 2026, including TD Cowen, Leerink Global Healthcare, Barclays Global Healthcare, and Jefferies Biotech on the Beach.
Each appearance is a fireside chat with specific times on March 3, 9, 10 and 11; replays will be posted in the Events and Presentations section of the company website.
Arvinas (Nasdaq: ARVN) will report fourth quarter and full year 2025 financial results on February 24, 2026. Management will review results and provide a corporate update via a live webcast at 8:00 a.m. ET.
The webcast is available under “Events and Presentations” on Arvinas’ investor website, and a replay will be posted on www.arvinas.com after the event.
Arvinas (Nasdaq: ARVN) announced that Randy Teel, Ph.D., has been appointed President, Chief Executive Officer, and director effective February 12, 2026. Teel succeeds John Houston, Ph.D., who is retiring as CEO and chair but will remain a board member and provide consulting services. Briggs Morrison, M.D., becomes board chair.
The release highlights Teel’s 20 years of industry experience, his role in Arvinas’ 2018 IPO, the company’s first positive pivotal PROTAC trial, demonstrated CNS pharmacodynamic activity, and over $2 billion raised through financings and partnerships.
PROTAC market (coverage: 7MM) is forecast to grow sharply through 2034 as targeted protein degradation advances across oncology and other indications. Key pipeline assets include vepdegestrant, luxdegalutamide, ASP3082, and DT2216. The report cites ~90 protein-degradation leads, ~20% in clinical development, and PROTACs representing >30% of the protein degradation pipeline. Strategic partnerships include Arvinas collaborations with Pfizer and Novartis, and a Novartis up-front payment of USD 150 million for ARV-766 rights. Notable trial data: Phase III VERITAC-2 met its ESR1m primary endpoint but not the ITT population.
Arvinas (NASDAQ: ARVN) presented preclinical data showing enhanced antitumor activity when its PROTAC BCL6 degrader ARV-393 is combined with glofitamab (CD20×CD3) at ASH 2025.
Key findings: concomitant ARV-393 (3 mg/kg) + glofitamab (0.15 mg/kg) produced 81% tumor growth inhibition (TGI) and sequential dosing produced 91% TGI vs 38% and 36% for each agent alone; higher-dose ARV-393 (6 mg/kg) combinations yielded markedly higher tumor regressions (10/10 and 7/8 mice vs 5/11 and 0/11 for single agents). RNA sequencing showed CD20 upregulation and increased interferon/antigen-presentation gene expression. Arvinas plans to initiate a Phase 1 combination cohort in DLBCL in 2026.
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The presentation is scheduled for Thursday, December 4, 2025 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s Events and Presentations web page.
Arvinas (Nasdaq: ARVN) announced multiple abstracts on vepdegestrant (ARV-471) accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), Dec 9–12, 2025 in San Antonio, TX.
Presentations include subgroup analyses from the phase 3 VERITAC-2 trial versus fulvestrant, ctDNA biomarker analyses from a phase 1/2 study, real-world ESR1 mutation prevalence after 1L therapy, an I-SPY2 endocrine optimization pilot, and a phase 1/2 trial of PF-07248144 combined with vepdegestrant. Pfizer is a development collaborator and Quantum Leap sponsors I-SPY2 EOP. Full abstracts available via the SABCS online program.